Davita (DVA) Upgraded at Bank of America

Davita (NYSE:DVA) was upgraded by investment analysts at Bank of America from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Thursday, January 4th, Marketbeat reports. The firm currently has a $85.00 target price on the stock, up from their previous target price of $75.00. Bank of America’s price objective points to a potential upside of 6.21% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Citigroup raised shares of Davita from a “neutral” rating to a “buy” rating and upped their price target for the company from $67.71 to $82.00 in a research note on Monday, December 11th. KeyCorp reaffirmed a “hold” rating on shares of Davita in a research note on Tuesday, October 10th. SunTrust Banks set a $57.00 price target on shares of Davita and gave the company a “hold” rating in a research note on Sunday, October 15th. Robert W. Baird reaffirmed a “hold” rating and set a $63.00 price target on shares of Davita in a research note on Friday, November 10th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and set a $64.00 price target on shares of Davita in a research note on Wednesday, September 6th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and two have issued a strong buy rating to the company’s stock. Davita has an average rating of “Hold” and an average price target of $78.22.

Davita (NYSE:DVA) traded up $1.96 during mid-day trading on Thursday, hitting $80.03. 2,360,600 shares of the stock traded hands, compared to its average volume of 1,749,325. Davita has a 1 year low of $52.51 and a 1 year high of $80.71. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.40 and a quick ratio of 1.35. The stock has a market capitalization of $14,510.00, a P/E ratio of 30.66, a PEG ratio of 15.06 and a beta of 0.96.

Davita (NYSE:DVA) last released its earnings results on Tuesday, November 7th. The company reported $0.81 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.13). Davita had a return on equity of 13.31% and a net margin of 3.40%. The company had revenue of $3.92 billion during the quarter, compared to analysts’ expectations of $3.91 billion. During the same period last year, the firm posted $0.95 EPS. Davita’s quarterly revenue was up 5.2% compared to the same quarter last year. equities analysts expect that Davita will post 3.42 EPS for the current fiscal year.

Davita declared that its board has authorized a share buyback plan on Tuesday, October 10th that permits the company to buyback $1.50 billion in outstanding shares. This buyback authorization permits the company to buy shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

In other news, VP Leanne M. Zumwalt sold 949 shares of the company’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $68.19, for a total value of $64,712.31. Following the transaction, the vice president now directly owns 12,423 shares in the company, valued at $847,124.37. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider James K. Hilger sold 5,608 shares of the company’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $69.46, for a total transaction of $389,531.68. Following the completion of the transaction, the insider now owns 47,649 shares in the company, valued at $3,309,699.54. The disclosure for this sale can be found here. Insiders have sold 117,937 shares of company stock worth $8,028,379 in the last quarter. Company insiders own 2.00% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of DVA. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Davita in the third quarter worth about $154,000. Eqis Capital Management Inc. lifted its stake in Davita by 62.5% in the third quarter. Eqis Capital Management Inc. now owns 7,473 shares of the company’s stock worth $444,000 after acquiring an additional 2,873 shares during the period. Accident Compensation Corp lifted its stake in Davita by 147.5% in the second quarter. Accident Compensation Corp now owns 15,100 shares of the company’s stock worth $978,000 after acquiring an additional 9,000 shares during the period. Xact Kapitalforvaltning AB lifted its stake in Davita by 22.8% in the third quarter. Xact Kapitalforvaltning AB now owns 19,851 shares of the company’s stock worth $1,179,000 after acquiring an additional 3,685 shares during the period. Finally, Cibc World Markets Corp lifted its stake in Davita by 35.3% in the second quarter. Cibc World Markets Corp now owns 22,006 shares of the company’s stock worth $1,425,000 after acquiring an additional 5,746 shares during the period. Hedge funds and other institutional investors own 87.94% of the company’s stock.

WARNING: “Davita (DVA) Upgraded at Bank of America” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://ledgergazette.com/2018/01/12/davita-dva-upgraded-to-buy-at-bank-of-america.html.

Davita Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply